HitGen Enters Into Research Collaboration with Global Blood Therapeutics

Chengdu, China January 8, 2016 – HitGen LtD, a privately held drug discovery company that enables the extraordinary power of DNA encoded libraries with a patented proprietary platform to discover new therapeutic starting points, announced today a research collaboration with Global Blood Therapeutics, Inc. (NASDAQ: GBT),  a clinical-stage biopharmaceutical company dedicated to novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs. HitGen will provide biology, chemistry, and screening to support GBT's efforts around an undisclosed novel target.

"We are pleased that Global Blood Therapeutics has chosen HitGen as a collaboration partner for these discovery efforts" said Dr Jin Li, CEO of HitGen Ltd. "We have built a great organization over the last three years. We continue to strive forward by providing better solutions for our partners that are both economically attractive and timely to fulfill unmet medical needs and relieve suffering".

About HitGen Ltd

HitGen's DEL platform contains over 4 billion novel small molecules and macrocycles designed with drug-like properties based on a diverse set of scaffolds, with tractable chemistry and proven results for finding drug leads against targets from known and novel protein classes. The library is populated with more than 780 distinct scaffolds, cyclic peptides, natural product-like and macrolide providing maximum versatility to interrogate a broad range of biological targets and protein-protein complexes.

For further information, please contact

Dr Jin Li, Chairman & CEO, HitGen Ltd. Tel: +86 028 85197385

Dr Bill Farley, VP, Business Development, HitGen Ltd. Tel: +1 516 318 2150